Phase 1 Trial of MuSK-CAART Therapy Is Recruiting

MuSK-CAART, an investigational cell-based therapy being developed to treat myasthenia gravis (MG) patients with anti-MuSK antibodies, eliminated disease-driving B-cells in a mouse model of the disease, a study showed. The findings, some of which were reported previously at a scientific conference, supported Cabaletta Bio’s request for a…